RhumbLine Advisers’s Tonix Pharmaceuticals TNXP Stock Holding History

RhumbLine Advisers’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222K	Buy	17,434 +3,266	+23%	+$42.1K	﹤0.01%	3230
2026 Q1	$195K	Buy	14,168 +1,433	+11%	+$22.1K	﹤0.01%	3131
2025 Q4	$199K	Buy	12,735 +529	+4%	+$9.75K	﹤0.01%	3179
2025 Q3	$295K	Buy	12,206 +908	+8%	+$33.7K	﹤0.01%	3005
2025 Q2	$406K	Sell	11,298 -2,372	-17%	-$62.2K	﹤0.01%	2812
2025 Q1	$244K	Buy	+13,670	New	+$277K	﹤0.01%	3005
2022 Q2	–	Sell	-1	Closed	-$86K	–	3234
2022 Q1	$86K	Hold	1	–	–	﹤0.01%	2915
2021 Q4	$129K	Hold	1	–	–	﹤0.01%	2908
2021 Q3	$202K	Hold	1	–	–	﹤0.01%	2913
2021 Q2	$358K	Buy	+1	New	+$735K	﹤0.01%	2720

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's TNXP Position: Q2 2026 in Review

RhumbLine Advisers increased its Tonix Pharmaceuticals (TNXP) stake by 23% in Q2 2026, buying an estimated $42.1K and bringing the position to 17,434 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3230.

RhumbLine Advisers first reported a position in TNXP in Q2 2021 and has held it in 10 quarters since. The position peaked at $406K in Q2 2025. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

RhumbLine Advisers held 17,434 shares of Tonix Pharmaceuticals worth $222K as of Q2 2026.
RhumbLine Advisers bought 3,266 Tonix Pharmaceuticals shares in Q2 2026, an estimated $42.1K.
Tonix Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3230 holding.
RhumbLine Advisers first reported a position in Tonix Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
RhumbLine Advisers's Tonix Pharmaceuticals position peaked at $406K in Q2 2025.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.